Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
Status:
Terminated
Trial end date:
2017-02-14
Target enrollment:
Participant gender:
Summary
The investigators evaluated the safety and efficacy of a short lead-in course (8 weeks) of
entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
National Center for Research Resources (NCRR) University of Pittsburgh